CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...
In a webcast released today, CLINUVEL’s Director of Global Operations, Lachlan Hay, provides insights on the Company’s Investor Relations programme, the launch of its first polychromatic screen and the use of SCENESSE® in Europe and the USA.
In an investor and analyst webinar hosted by CLINUVEL, Mr Malcolm Bull, Head of Investor Relations, is joined by Mr Darren Keamy, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, in discussing the financial results for the year ended 30 June 2022 and the Company’s plans for FY2023 and beyond.
In a webcast addressed to shareholders, CLINUVEL’s Managing Director, Dr Philippe Wolgen, covers CLINUVEL’s market position, financial management and the Group’s unfolding growth and expansion strategy.